Biogen (BIIB) PT Lowered to $240 at RBC Capital
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $222.67 +3.07%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 32
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $240.00 (from $242.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Sprinklr Inc (CXM) PT Raised to $7.50 at Cantor Fitzgerald
- ONEOK Inc (OKE) PT Raised to $104 at Truist Securities
- Enovis Corp (ENOV) PT Lowered to $27 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
